Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant in ACTH-dependent Cushing's Syndrome
NCT05804669Phase 2Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
A Phase 2 trial of atumelnant in ACTH-dependent Cushing's syndrome, sponsored by Crinetics Pharmaceuticals. Started Oct 2023; status: completed.
02
Drugs
atumelnant
03
Conditions
ACTH-dependent Cushing's syndrome
Beyond the preview
Go deeper on NCT05804669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804669.